LFG
IMVT icon

Larson Financial Group’s Immunovant IMVT Stock Holding History

Larson Financial Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.08K Sell
80
-17
-18% -$518 ﹤0.01% 2968
2026
Q1 		$2.41K Hold
97
– – ﹤0.01% 2900
2025
Q4 		$2.47K Buy
97
+55
+131% +$1.23K ﹤0.01% 2716
2025
Q3 		$677 Buy
42
+11
+35% +$178 ﹤0.01% 3025
2025
Q2 		$496 Buy
+31
New +$469 ﹤0.01% 2858

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's IMVT Position: Q2 2026 in Review

Larson Financial Group reduced its Immunovant (IMVT) stake by 18% in Q2 2026, selling an estimated $518 and leaving 80 shares worth $3.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2968.

Larson Financial Group first reported a position in IMVT in Q2 2025 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Larson Financial Group held 80 shares of Immunovant worth $3.08K as of Q2 2026.
  • Larson Financial Group sold 17 Immunovant shares in Q2 2026, an estimated $518.
  • Immunovant made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2968 holding.
  • Larson Financial Group first reported a position in Immunovant in Q2 2025 and has held it in 5 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.